Insider Selling: Natera (NASDAQ:NTRA) CFO Sells $430,156.80 in Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 1,867 shares of the stock in a transaction on Thursday, January 29th. The shares were sold at an average price of $230.40, for a total value of $430,156.80. Following the sale, the chief financial officer owned 59,059 shares of the company’s stock, valued at approximately $13,607,193.60. This represents a 3.06% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, January 28th, Michael Burkes Brophy sold 2,413 shares of Natera stock. The stock was sold at an average price of $237.56, for a total value of $573,232.28.
• On Tuesday, January 27th, Michael Burkes Brophy sold 784 shares of Natera stock. The stock was sold at an average price of $240.53, for a total transaction of $188,575.52.
• On Wednesday, January 21st, Michael Burkes Brophy sold 37,175 shares of Natera stock. The stock was sold at an average price of $242.54, for a total transaction of $9,016,424.50.
• On Tuesday, January 20th, Michael Burkes Brophy sold 23,948 shares of Natera stock. The stock was sold at an average price of $234.74, for a total value of $5,621,553.52.

Natera Stock Down 0.1%

Natera stock opened at $231.14 on Friday. Natera, Inc. has a 52 week low of $125.38 and a 52 week high of $256.36. The stock has a 50-day moving average price of $235.91 and a 200 day moving average price of $194.11. The company has a market capitalization of $31.97 billion, a price-to-earnings ratio of -100.93 and a beta of 1.62.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). The business had revenue of $592.18 million during the quarter, compared to analyst estimates of $514.55 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The firm’s revenue was up 34.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.26) EPS. Research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Natera News Summary

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera announced completion of enrollment in the randomized ACES‑EMB heart‑transplant trial — a clinical milestone for the transplant franchise (Prospera) that de‑risks the program’s pathway to clinical readouts and potential uptake. Article Title
• Positive Sentiment: Wall Street coverage remains largely favorable: multiple firms maintain buy/outperform views and several have raised targets (MarketBeat summary shows consensus around a “Moderate Buy” and an average target near $249). This supports upside expectations if results and growth continue.
• Neutral Sentiment: Natera reported preliminary Q4 revenue (details in the alert). Preliminary figures may influence sentiment when the final quarter report and guidance are released; investors should watch the formal Q4 release for confirmation versus consensus. Preliminary Q4 Revenue
• Neutral Sentiment: Institutional ownership remains extremely high (~99.9%), which tends to stabilize the shareholder base but can also concentrate selling/Buying flows when large holders move. (Source: MarketBeat summary.) Institutional Data
• Negative Sentiment: Multiple insider sales by senior executives: CFO Michael Burkes Brophy sold several tranches (totaling 5,064 shares across Jan. 20–29) and CEO Steven Chapman sold several thousand shares (roughly 5,970 shares across Jan. 27–28). These trades total millions of dollars and may create short‑term selling pressure despite insiders retaining large residual stakes. CFO Form 4 CEO Form 4
• Negative Sentiment: Other insiders (John Fesko, Solomon Moshkevich) also sold smaller tranches. While each reduction is under ~1% of those insiders’ holdings, the cluster of sales amplifies negative signaling to the market. Fesko Form 4 Moshkevich Form 4

Wall Street Analysts Forecast Growth

NTRA has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a research note on Thursday, January 22nd. Piper Sandler lifted their target price on shares of Natera from $220.00 to $230.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. Citigroup began coverage on Natera in a report on Wednesday, January 7th. They set a “buy” rating and a $300.00 target price on the stock. Canaccord Genuity Group reissued a “buy” rating on shares of Natera in a research report on Monday, January 12th. Finally, Zacks Research raised shares of Natera from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $249.20.

Institutional Investors Weigh In On Natera

Several large investors have recently added to or reduced their stakes in the business. Flagship Harbor Advisors LLC purchased a new position in Natera in the 4th quarter valued at approximately $41,000. Hilltop National Bank purchased a new position in Natera in the second quarter valued at $33,000. Horizon Investments LLC purchased a new position in Natera in the third quarter valued at $32,000. Sound Income Strategies LLC increased its holdings in Natera by 95.7% during the 3rd quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock worth $39,000 after purchasing an additional 110 shares during the period. Finally, TD Waterhouse Canada Inc. acquired a new stake in Natera in the 4th quarter valued at about $62,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.